Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes

被引:0
|
作者
Banta-Green, Caleb J. [1 ,2 ,3 ]
Owens, Mandy [1 ,4 ]
Williams, Jason R. [1 ]
Floyd, Anthony S. [1 ]
Williams-Gilbert, Wendy [1 ]
Kingston, Susan [1 ]
机构
[1] Univ Washington Seattle, Sch Med, Dept Psychiat & Behav Sci, Addict Drug & Alcohol Inst, Seattle, WA USA
[2] Univ Washington Seattle, Sch Publ Hlth, Dept Hlth Syst & Populat Hlth, Seattle, WA USA
[3] Univ Washington Seattle, Sch Publ Hlth, Dept Epidemiol, Seattle, WA USA
[4] Univ Washington, Dept Psychol, Seattle, WA USA
来源
关键词
opioid use disorder; medications for opioid use disorder; multi-site study; low-barrier care; harm reduction; BUPRENORPHINE TREATMENT; COLLABORATIVE CARE; HOMELESSNESS; INCREASES; SERVICES; PROGRAM;
D O I
10.2147/SAR.S475807
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Purpose: A large treatment gap exists for people who could benefit from medications for opioid use disorder (MOUD). People OUD accessing services in harm reduction and community-based organizations often have difficulty engaging in MOUD at opioid treatment programs and traditional health care settings. We conducted a study to test the impacts of a community-based medications first model of care in six Washington (WA) State communities that provided drop-in MOUD access. Participants and Methods: Participants included people newly prescribed MOUD. Settings included harm reduction and homeless services programs. A prospective cohort analysis tested the impacts of the intervention on MOUD and care utilization. Intervention impacts on mortality were tested via a synthetic comparison group analysis matching on demographics, MOUD history, and geography using WA State agency administrative data. Results: 825 people were enrolled in the study of whom 813 were matched to state records for care utilization and outcomes. Cohort analyses indicated significant increases for days' supply of buprenorphine, months with any MOUD, and months with any buprenorphine for people previously on buprenorphine (all results p<0.05). Months with an emergency department overdose did not change. Months with an inpatient hospital stay increased (p<0.05). The annual death rate in the first year for the intervention group was 0.45% (3 out of 664) versus 2.2% (222 out of 9893) in the comparison group in the 12 months; a relative risk of 0.323 (95% CI 0.11-0.94). Conclusion: Findings indicated a significant increase in MOUD for the intervention group and a lower mortality rate relative to the comparison group. The COVID-19 epidemic and rapid increase in non-pharmaceutical-fentanyl may have lessened the intervention impact as measured in the cohort analysis. Study findings support expanding access to a third model of low barrier MOUD care alongside opioid treatment programs and traditional health care settings.
引用
收藏
页码:173 / 183
页数:11
相关论文
共 50 条
  • [1] Drug court utilization of medications for opioid use disorder in high opioid mortality communities
    Marlowe, Douglas B.
    Theiss, David S.
    Ostlie, Erika M.
    Carnevale, John
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 141
  • [2] Outcomes of the Community-Based Medication-First Program for Opioid Use Disorder: A Multisite Hybrid Implementation Study
    Banta-Green, Caleb
    Owens, Mandy
    Williams, Jason
    Floyd, Anthony
    Sears, Jeanne
    Williams-Gilbert, Wendy
    Kingston, Susan
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [3] Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina
    Oros, Sarah M.
    Christon, Lillian M.
    Barth, Kelly S.
    Berini, Carole R.
    Padgett, Bennie L.
    Diaz, Vanessa A.
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, 2021, 56 (01): : 14 - 39
  • [4] Use of Medications for Opioid Use Disorder and Child Welfare Outcomes
    Muhar, Alexandra
    McNeer, Elizabeth
    Presley, Lauren D.
    Morad, Anna
    Loch, Sarah F.
    Dupont, William D.
    Patrick, Stephen W.
    [J]. JAMA HEALTH FORUM, 2024, 5 (07):
  • [5] Educating the community about the opioid epidemic and medications for opioid use disorder
    Williams, Jill M.
    Syed, Muzdalifa A.
    Adesanya, Aderike
    Gardner, George
    Chaguturu, Vamsee
    Coppola, Kristen M.
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2022, 31 (05): : 433 - 440
  • [6] Development of a Community-Based Wastewater Surveillance System to Measure Opioid, Stimulant and Medications for Opioid Use Disorder in the COVID-19 Pandemic
    Chai, Peter
    Getzinger, Gordon
    Suzuki, Joji
    Buben, Alex
    Boyce, Matthew
    Hess, Kait
    Wahl, Kelly
    Matus, Mariana
    Erickson, Timothy
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [7] Medications for opioid use disorder: bridging the gap in care
    Volkow, Nora D.
    [J]. LANCET, 2018, 391 (10118): : 285 - 287
  • [8] Medications for Opioid Use Disorder in the Criminal/Legal System: Knowledge, Beliefs, and Attitudes Among Rural Community-Based Stakeholders
    Victor, Grant
    Lee, Guijin
    del Pozo, Brandon
    Silverstein, Sydney
    Zettner, Catherine
    Cason, Rahni
    Ray, Bradley
    [J]. JOURNAL OF DRUG ISSUES, 2022, 52 (03) : 389 - 405
  • [9] Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality
    Krawczyk, Noa
    Jent, Victoria
    Hadland, Scott E.
    Cerda, Magdalena
    [J]. JOURNAL OF ADDICTION MEDICINE, 2022, 16 (01) : 114 - 117
  • [10] Outcomes associated with the use of medications for opioid use disorder during pregnancy
    Krans, Elizabeth E.
    Kim, Joo Yeon
    Chen, Qingwen
    Rothenberger, Scott D.
    James, Alton Everette
    Kelley, David
    Jarlenski, Marian P.
    [J]. ADDICTION, 2021, 116 (12) : 3504 - 3514